>APPX – It was trading around $10-11 when the whole heparin thing came out.<
This is an example of market inefficiency: the contaminated-heparin episode did not create value for heparin producers in the aggregate but rather transferred value from BAX to APPX. Yet BAX’s share price was unaffected by the episode.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”